PPARG and cancer: In 1998, Mueller et al. performedone of the first PPARγ agonist studies in a cancer setting [1].They demonstrated that both 15d-PG-J2and rosiglitazone (Rosi) could induce changes inepithelial gene expression associated with a more differentiated, lessmalignant state.